Search tips
Search criteria 


Logo of blackwellopenThis ArticleFor AuthorsLearn MoreSubmit
The Febs Journal
FEBS J. 2008 June; 275(11): 2779–2794.
PMCID: PMC2655357

Characterization of Aquifex aeolicus 4-diphosphocytidyl-2C-methyl-d-erythritol kinase – ligand recognition in a template for antimicrobial drug discovery


4-Diphosphocytidyl-2C-methyl-d-erythritol kinase (IspE) catalyses the ATP-dependent conversion of 4-diphosphocytidyl-2C-methyl-d-erythritol (CDPME) to 4-diphosphocytidyl-2C-methyl-d-erythritol 2-phosphate with the release of ADP. This reaction occurs in the non-mevalonate pathway of isoprenoid precursor biosynthesis and because it is essential in important microbial pathogens and absent from mammals it represents a potential target for anti-infective drugs. We set out to characterize the biochemical properties, determinants of molecular recognition and reactivity of IspE and report the cloning and purification of recombinant Aquifex aeolicus IspE (AaIspE), kinetic data, metal ion, temperature and pH dependence, crystallization and structure determination of the enzyme in complex with CDP, CDPME and ADP. In addition, 4-fluoro-3,5-dihydroxy-4-methylpent-1-enylphosphonic acid (compound 1) was designed to mimic a fragment of the substrate, a synthetic route to 1 was elucidated and the complex structure determined. Surprisingly, this ligand occupies the binding site for the ATP α-phosphate not the binding site for the methyl-d-erythritol moiety of CDPME. Gel filtration and analytical ultracentrifugation indicate that AaIspE is a monomer in solution. The enzyme displays the characteristic α/β galacto-homoserine-mevalonate-phosphomevalonate kinase fold, with the catalytic centre positioned in a deep cleft between the ATP- and CDPME-binding domains. Comparisons indicate a high degree of sequence conservation on the IspE active site across bacterial species, similarities in structure, specificity of substrate recognition and mechanism. The biochemical characterization, attainment of well-ordered and reproducible crystals and the models resulting from the analyses provide reagents and templates to support the structure-based design of broad-spectrum antimicrobial agents.

Keywords: enzyme–ligand complex, GHMP kinase, isoprenoid biosynthesis, molecular recognition, non-mevalonate pathway

Isoprenoids are one of the largest groups of natural products and include primary and secondary metabolites such as sterols, dolichols and triterpenes, the prenyl groups of chlorophyll and modified proteins. Isoprenoids contribute to important biological functions including respiration, photosynthesis, hormone-based signalling, apoptosis, meiosis and protein degradation, and in addition, provide important structural components of cell membranes [13].

Two biosynthetic pathways to isopentenyl diphosphate and dimethylallyl disphosphate, the basic five-carbon precursors for all isoprenoids, have evolved. The mevalonate pathway, named after one of its constituent metabolites, is found in archaebacteria, some eubacteria, yeast, the cytosolic compartment of plants and animals. In chloroplasts, algae, cyanobacteria, most eubacteria and the apicomplexa, the biosynthesis of isopentenyl diphosphate and dimethylallyl disphosphate is via the non-mevalonate pathway [47]. Species that utilize and are dependent on the non-mevalonate pathway include the causal agents for important human diseases such as leprosy, tuberculosis and malaria. The enzymes of this pathway are absent from humans and have attracted interest as potential targets for antimicrobial drug screening [8], structure-based drug discovery and design [4].

Our interest centres on 4-diphosphocytidyl-2C-methyl-d-erythritol kinase (IspE, EC, which catalyses the transfer of the ATP γ-phosphate to 4-diphosphocytidyl-2C-methyl-d-erythritol (CDPME) forming 4-diphosphocytidyl-2C-methyl-d-erythritol 2-phosphate (CDPME2P) and ADP (Fig. 1) [9,10]. IspE is a GHMP kinase, named after the four founding members of this protein superfamily namely galacto, homoserine, mevalonate and phosphomevalonate kinases [11,12]. The crystal structure of the Escherichia coli orthologue (EcIspE) in complex with a stable ATP analogue, adenosine 5′-(β,γ-imino)triphosphate (AMP-PNP) and CDPME, as well as the apo-structure of the Thermus thermophilus enzyme (TtIspE) have been reported [13,14].

Fig. 1
The reaction catalysed by IspE together with the structure of 1 to highlight similarity with part of the substrate.

Research with IspE from several organisms has been hampered because the recombinant proteins have low solubility. Here, we show that IspE from the thermophilic bacterium Aquifex aeolicus (AaIspE) provides an efficient expression system of a stable and soluble recombinant enzyme. This has allowed, for the first time, detailed biochemical and kinetic characterization of IspE, determination of the metal ion and temperature dependence and optimum pH. The enzyme gives well-ordered crystals and we applied multiple-wavelength anomalous dispersion phasing methods to a selenomethionine (SeMet) derivative to solve the structure. Complexes with cytidine, CDP, CDPME, ADP and the newly synthesized ligand, 4-fluoro-3,5-dihydroxy-4-methylpent-1-enylphosphonic acid (1), are reported.

Results and Discussion

Biochemical and kinetic characterization

The putative ispE gene from A. aeolicus was placed under the control of the T7 promoter and lac operator in the hyperexpression plasmid pET-15b, and heat transformed into E. coli BL21 (DE3). The gene was preceded by a His6 tag to enable purification of the recombinant protein via metal-chelating affinity chromatography. The polyhistidine tag was removed by thrombin-mediated proteolysis, followed by purification with anion-exchange chromatography. The protein was purified to homogeneity with a yield of ~ 15 mg protein per litre of cell culture. The protein had an apparent mass of 30 kDa, as judged by gel-filtration chromatography, which is in a good agreement with a sedimentation velocity experiment affording a calculated mass of 29.8 kDa (data not shown).

The catalytic activity of the recombinant IspE protein was measured by 13C NMR spectroscopy and photometry. The 13C NMR measurement was performed using the multiply 13C-labelled substrate [1,3,4-13C3]CDPME to enhance the sensitivity and selectivity of 13C observation. 13C NMR signals detected in a typical NMR assay are shown in Fig. 2. The chemical shifts as well as the 13C13C-coupling constants were in excellent agreement with the published data on CDPME [15] and CDPME2P [9]. Optimal activity was identified at pH 8.5 and ~ 60 °C (Fig. 3). AaIspE was catalytically active in the presence of various metal ions (Table 1), and a highest rate of 1.5 μmol·min−1·mg−1 was achieved in the presence of 2 mm Mg2+ or Mn2+ (Fig. 4). The photometric assay was performed according to a published procedure [8] using auxiliary enzymes to observe the decrease in NADH absorption at 340 nm. The KM values for CDPME and ATP were determined as 121 and 222 μm, respectively (Table 2, Fig. 5). The data are similar to the kinetic properties reported for IspE from E. coli [16] and tomato [17], respectively.

Table 1
Metal ion dependence of AaIspE. Measurements were performed using the NMR assay as described in Experimental procedures with 5 mm divalent metal ions.
Table 2
Kinetic parameters of AaIspE.
Fig. 2
13C NMR spectra of an enzymatic assay with AaIspE. (A) Signals of [1,3,4-13C3]CDPME before incubation; (B) 65% conversion from [1,3,4-13C3] CDPME into [1,3,4-13C3] CDPME2P. The 13C NMR signals of the substrate and the product agree published data [8]. ...
Fig. 3
pH and temperature dependence of AaIspE. (A) Relative activity versus pH. The measurements were performed using the photometric assay as described in Experimental procedures in a buffer containing 50 mm citrate, 50 mm Hepes, 50 mm Tris/HCl and 50 mm boric ...
Fig. 4
Mg2+ and Mn2+ dependence. The optimum concentration of both metals is 2 mm.
Fig. 5
Substrate dependence of AaIspE. (A) Michaelis–Menten kinetics showing initial rate versus ATP concentration. (B) Michaelis–Menten kinetics showing initial rate versus CDPME concentration; insets, Lineweaver–Burk; dotted lines show ...

Overall structure of AaIspE

Ordered and reproducible crystals of AaIspE were obtained and multiple-wavelength anomalous dispersion methods were applied to obtain the initial phases. Subsequently, three medium-resolution complex crystal structures were determined (Tables 3 and 4). The crystals are isomorphous with two molecules, total molecular mass ~ 60 kDa, in the asymmetric unit. The molecules, A and B, are related by a non-crystallographic twofold axis (data not shown). The surface area between the two molecules is ~ 540 Å per molecule, ~ 4% of the total surface area of the protein. This low value is consistent with gel-filtration and ultracentrifugation experiments that indicate AaIspE is a monomer in solution (data not shown).

Table 3
Multiple-wavelength anomalous dispersion data statistics. Numbers in parentheses are for the highest resolution shell, a bin of 0.15 Å.

There are two molecules per asymmetric unit and therefore the three crystal structures provide six crystallographically independent molecules. These molecules are highly similar. Pair-wise least-squares superpositions give a range of r.m.s.d. of 0.17–0.46 Å for all Cα positions with a mean of 0.33 Å. Only minor differences are observed in the conformation of flexible side chains on α6 and the loop region following α4. The binding mode of the ligands differs only slightly within the asymmetric units and will be described in detail when applicable.

Table 4
Crystallographic statistics. Numbers in parentheses represent the highest resolution bin of width ~ 0.06 Å.

AaIspE displays the typical GHMP kinase fold that comprises two domains (Fig. 6) [13]. The N-terminal domain (residues 1–155) consists of an elongated six-stranded β sheet (β1–β6). In addition, the concave side of the β sheet is flanked by three α helices (α1–α3) and two 310 helices (θ1 and θ2). The C-terminal domain comprises an antiparallel four-stranded β sheet (β7–β10), bordering β1 and β2 of the N-terminal domain, four α helices (α4–α7) and two 310 helices (θ3 and θ4).

Fig. 6
Ribbon diagram of AaIspE. α and 310 helices are red and β strands are cyan. Secondary structure elements have been labelled, N- and C-termini are marked. ADP is gold, the substrate CDPME green.

GHMP kinases have three conserved motifs that help create the catalytic centre [12,18,19]. In AaIspE (Fig. 7) the residues of motif 1 (Lys9 to Leu14) are on β1 of the N-terminal domain and interact with CDPME, residues of motif 2 (Ile87 to Ser98) and motif 3 (Val235 to Val242), interact with the triphosphate component of ATP (see later). Motif 3 comprises the β8–β9 loop, which does not interact with the ligands but stabilizes the conformation of motifs 1 and 2 via hydrogen-bonding contacts. For example, Ser236 OG and Gly237 N form contacts with Asn11 OD1 of motif 1, Ser236 OG interacts with Gly92 O of motif 2, whereas Ser240 N and Thr241 OG1 donate hydrogen bonds to Gly90 O and Ala91 O respectively (not shown). Motif 2 is part of the β4–α2 loop, commonly described as the phosphate binding or P-loop. The main-chain amides of this glycine-rich motif and the α3 dipole surround the negatively charged phosphates of the nucleotide. The details of interactions formed between the enzyme motifs together with additional parts of the active site and the ligands are presented after comparison with structures of IspE orthologues.

Fig. 7
Primary and secondary structure of AaIspE and sequence alignment of A. aeolicus (Aa), E. coli (Ec) and M. tuberculosis (Mtb) orthologues. Residues conserved in all three sequences are boxed in black, those conserved in two of the three sequences are boxed ...

Comparison of IspE structures

AaIspE shares the highest sequence identity with TtIspE (32%) and slightly less with EcIspE (30%). The alignment of EcIspE with AaIspE in shown in Fig. 7. The DALI server [20] identified EcIspE (Z-score: 29.1) and TtIspE (Z-score: 27.7) as most similar to AaIspE. (The Z-score is a measure of the statistical significance of the best subunit–subunit alignment and was determined by DALI. Typically, dissimilar proteins will have a Z-score < 2.0.) Cα superpositions of EcIspE and TtIspE with AaIspE give r.m.s.d values of 1.6 and 1.8 Å, respectively, which mainly correspond to differences in the C-terminal domain distant from the active site. An overlay of AaIspE and EcIspE structures is depicted in Fig. 8. In general, the fold and secondary structure are well conserved. With respect to AaIspE, α5 and α7 are situated at different positions in EcIspE (Fig. 8) and TtIspE structures, and an additional helix following β10 is inserted in EcIspE. The two structures are further decorated with a 310 helix following α7 or α4 respectively (not shown). The structural comparison and alignment of AaIspE with EcIspE reveals a high degree of conservation within the active site (Fig. 8). Alignment of the Mycobacterium tuberculosis IspE (MtbIspE) sequence with those of AaIspE and EcIspE indicates sequence identities of around 25% (Fig. 7). This comparison is detailed later.

Fig. 8
Stereo-view Cα overlay of AaIspE and EcIspE. AaIspE is shown in red with EcIspE in black. Also depicted are the ADP (gold) and CDPME (green) from the AaIspE complex I. The positions of α5 and α7 are marked.

The substrate-binding site

Three crystal structures of AaIspE in complex with ligands were determined. Although data for complex I were measured from AaIspE co-crystallized with the relatively stable ATP analogue AMP-PNP only ADP could be modeled. Similarly, CDPME2P was present in the crystallization conditions for the sample used to derive complex II, but only CDPME was observed. The lack of electron density for the terminal phosphate groups of CDPME2P and AMP-PNP is either a result of disorder and/or hydrolysis. In complex III, cytidine, ADP and 1 are present. The structures and interactions formed between AaIspE and the ligands are similar in each complex and we concentrate on the details of complex II to indicate how substrate and ADP bind and then describe the specifics of interactions with 1.

The substrate CDPME binds into a deep cavity between the N- and C-terminal domains, surrounded by residues on β1, α4, the N-terminal end of β2 and θ2 and the β5-β6 loop (Fig. 6). His25 forms three hydrogen bonds to the pyrimidine (Fig. 9A). The imidazole ND1 and main-chain amide donate hydrogen bonds to the nucleotide O2 and N3 respectively, whereas the carbonyl accepts a hydrogen bond from N4. N4 further interacts with the main-chain carbonyl of Lys145. The cytosine position is also stabilized by hydrophobic contacts with the side chains of Tyr24 and Tyr175, the latter forming π–π stacking interactions with the cytidine. Tyr175 is replaced in EcIspE by a phenylalanine, a conservative substitution and we note a degree of flexibility for this side chain because it adopts slightly different conformations in the three AaIspE complex structures and with elevated thermal parameters compared with the more buried Tyr24. A large aromatic residue at this position in the active site may act as a gatekeeper during substrate binding and product release.

Fig. 9
IspE ligand interactions in complex I. In both sections of this figure atoms are coloured blue N, red O and orange P. The C atoms of protein are beige, of CDPME green and ADP yellow. Residues that interact with the ligands are labelled, water molecules ...

The ribose is solvent accessible and water-mediated contacts link O2′, Ser176 OG and the main-chain carbonyl of Gly172. The α-phosphate accepts a hydrogen bond donated from the main-chain amide of Ala129, and the β-phosphate interacts with Ser128 OG, the amide of Asp130 and also, via a solvent-mediated bridge, with Ser97 OG (not shown). The erythritol moiety of CDPME protrudes into a cavity in which catalytic residues Lys9 and Asp130 are placed. An extensive network of hydrogen-bonding interactions positions key residues and functional groups on substrate to support catalysis. Lys9 NZ is held in place by a hydrogen bond with Asn11 OD1. Three additional hydrogen bonds serve to position Asn11. OD1 also accepts a hydrogen bond donated from the main-chain amide of Gly237 and ND2 donates hydrogen bonds to Thr29 OG1 and to the substrate O1M hydroxyl. O1M forms a bidentate interaction with Asp130 OD1 and OD2. The O3M hydroxyl interacts with Tyr175 OH and a well-ordered water molecule that, in turn, forms hydrogen bonds with the main-chain carbonyl of Lys145 and Asp130 OD1 (data not shown). The methyl substituent on C2 is directed towards a hydrophobic pocket formed by the side chains of Tyr175 and Leu208.

The O2M group, where phosphate addition occurs, participates in hydrogen bonds with Lys9 NZ, Asp130 OD2 and a water molecule (not shown) that in turn associates with the main-chain amide and OG of Ser238, and β-phosphate of ADP. The placement and interactions formed by O2M are consistent with a mechanism that involves polarization of the hydroxyl group and Asp130 acting as a general base in proton abstraction to generate a nucleophile. This can then attack and acquire the reactive γ-phosphate of ATP with Lys9 NZ, and Ser238 amide and OG groups placed to stabilize the transition state. An overlay of the EcIspE AMPPNP complex [13] with AaIspE places the γ-phosphate group towards the catalytic residues Lys9 and Asp130 in a position consistent with the proposed mechanism (not shown).

In complex I, CDP displays a single conformation in molecule A and three in molecule B (not shown). Such conformational freedom, distinct from the ordered substrate, may reflect loss of the methylerythritol component and the numerous stabilizing interactions that it forms deep within the enzyme active site. The cytosine moieties of the four CDP molecules interact with Tyr24, His25, Lys145 and Tyr175, as described previously, with differences (not shown) confined to the orientation and binding modes of the solvent-exposed ribose and phosphate groups. In molecules A and B, the ribose O2′ interacts with the carbonyl of Gly23 via a water molecule. In addition, in molecule A, this group also interacts with the Gly172 carbonyl and Ser176 OG via water molecules; the α-phosphate interacts with Ser138 OG via a water molecule and the β-phosphate forms a direct hydrogen bond with Tyr24 OH. One CDP conformer in molecule B is similar to that observed in molecule A. In the second conformer in molecule B the α-phosphate occupies a similar position but the β-phosphate group is directed out of the active site to interact with both Tyr24 OH and the carbonyl of Ile127. This latter interaction suggests that protonation of the phosphate has occurred. In the third conformer the α-phosphate interacts with the backbone amide of Gly172, the β-phosphate group with the Ser169 carbonyl, Thr171 amide and OG1.

The ATP-binding site

ADP binds in a cavity formed by the N-terminal domain adjacent to the CDPME-binding site (Figs 6 and 9B). The ADP is surrounded by residues in β2, at the N-terminal end of α1 and α2 and in the β4–α2 and β3–θ1 loops. ATP generally binds to kinases with the purine in an anti conformation with respect to the ribose. There are, however, two exceptions in which the energetically less favourable syn conformation is observed, EcIspE [13] and the related homoserine kinase [21]. In AaIspE the syn conformation is also observed with the adenine moiety placed in a hydrophobic cleft surrounded by aliphatic side chains of Ile53, Ile55, Leu61, Ile83 and Lys85 with contributions from Pro89 and Gly96. The purine conformation is stabilized by hydrogen-bonding contacts. Two asparagines (Asn60 and Asn99), themselves positioned by a network of hydrogen-bonding interactions, are placed to accept hydrogen bonds donated by adenine N6. Asn60 OD1 interacts with the amide of Val62, ND2 forms water-mediated contacts with Val49 and Ile55 carbonyl groups. Asn99 OD1 accepts hydrogen bonds from adenine N6 and Lys85 NZ, ND2 interacts with Ser6 OG and Asp38 OD2. Adenine N1 also interacts with Lys85 NZ, which is held in place by interaction with Asp38 and via a water molecule with the ADP α-phosphate. The amide of Leu61 donates a hydrogen bond to adenine N7. The ribose and phosphate groups of the ADP are solvent accessible and the α–β-linking oxygen forms a water-mediated contact with the Pro88 carbonyl and Leu93 amide. The β-phosphate accepts hydrogen bonds donated by amides of Gly92 and Gly94, and is linked to the Gly239 and Ser169 carbonyls, Lys9, Asp130 and Ser238 side-chain groups via water molecules. Another water-mediated interaction is formed between Thr171 OD1 and the ADP β-phosphate. In AaIspE and EcIspE complex structures, the adenine and ribose moieties bind in a similar position with highly conserved hydrogen-bonding interactions. The phosphate groups, however, adopt different conformations in the two structures, which may simply reflect the difference between AMP-PNP present in the EcIspE structure and ADP in AaIspE (not shown). The amide of Gly97 binds to the ADP α-phosphate in AaIspE, whereas the corresponding Gly107 of EcIspE coordinates to the β-phosphate. Furthermore, the Gly103 amide binds to the AMP-PNP γ-phosphate in EcIspE, whereas it is the β-phosphate that binds to the amide of the corresponding Gly92 in AaIspE.

Based on comparisons of the apo-structure of TtIspE with the Mg2+-bound crystal structures of homoserine kinase [21] and mevalonate kinase [22] Wada et al. [14] suggested that a metal ion would bind to Ser95 and Asp125 (corresponding to Ser97 and Asp130 in AaIspE). To investigate metal-ion binding in the catalytic site, AaIspE was co-crystallized in the presence of 20 mm magnesium chloride or manganese chloride together with ADP or AMP-PNP and several crystal structures determined at medium resolution (data not shown). However, despite the clear dependence of activity on divalent cations, and in similar fashion to EcIspE [13], we were unable to identify the position of any ordered metal ions in the active site of AaIspE.

Synthesis and binding of compound 1

The conjugated fluoro-MEP derivative compound 1 was designed as a fragment mimic of the β-phosphate and erythritol moiety of the substrate CDPME. The compound was expected to be a competitive inhibitor and to bind in a similar position to that observed for that component of the substrate represented in complex II. It was first necessary to determine a synthetic method for the molecule. Synthesis of 1 began with the enantiomerically pure fluorodiol 2, which was protected to afford the triol 3 (Scheme 1). Removal of the para-methoxybenzyl (PMB) was achieved by use of Yu’s Lewis acid catalyzed conditions to give 4. The free primary alcohol was then oxidized under Swern conditions and the resulting aldehyde 5 subjected to a Horner–Wadsworth Emmons olefination to afford the E-conjugated phosphonate ester 6 in quantitative yield and as a single double bond isomer. Double bond geometry was assigned by 1H NMR analysis (J =17 Hz). The silyl protecting groups were removed under standard trifluoroacetic acid (TFA) conditions to give the free 1,3-diol 7 in good yield.

Scheme 1
The outline for synthesis of the protected phosphonate ester compound 6.

Having unmasked the diol functionality, it was then necessary to free the vinyl phosphate. Treatment of 7 with bromotrimethylsilane (TMSBr) generated the desired enantiomerically pure vinyl phosphate 1 in reasonable yield (Scheme 2).

Scheme 2
Deprotection of compound 6 to produce compound 1.

We were unable to detect any ligand binding or enzyme inhibition of AaIspE by 1 (data not shown), suggesting low affinity for the enzyme. However, we were able to determine the crystal structure of the complex where the ligand was bound to one molecule of the asymmetric unit following soaking of a crystal in a solution of 1. Analysis reveals that 1 binds with the phosphonate occupying a similar position to that observed for the ADP/ATP α-phosphate not the β-phosphate of substrate (Fig. 10). The phosphate is positioned by hydrogen bonding to the main-chain amides Gly95 and Gly96, and water-mediated interactions with the carbonyl of Pro88, the amide of Leu93 together with the amide and OG groups of Ser97. The ligand C3 OH interacts with the amide groups of Leu93 and Gly94, the fluorine substituent at C4 with Ser238 OG and, via a water molecule, also with the carbonyl groups of Ser169 and Gly239, and Thr171 OD1. The C5 hydroxyl makes one hydrogen bond to a water molecule and is 3.2 Å from Lys9 NZ, although in the latter case the geometry is not optimal for a hydrogen bonding interaction.

Fig. 10
Stereo-view of compound 1 bound in the active site. The map, purple mesh, has been calculated with coefficients |FoFc| and αc, and contoured at 2.5σ. Fo represents the observed structure factors, Fc represents the calculated structure ...

AaIspE represents a template for inhibitor development

M. tuberculosis is a particularly important human pathogen. Approximately one-third of the world’s population is infected with this organism, the causative agent of tuberculosis, which was responsible for an estimated 1.6 million deaths in 2005 [23]. The need for novel chemotherapeutics in the treatment of M. tuberculosis infection is clearly demonstrated by its high infectivity rate, the prolonged and extensive therapy requirements and the increase in drug-resistant forms. New targets for drug discovery research are urgently sought and the non-mevalonate pathway provides potentially valuable enzymes for such use [24,25]. Our studies of MtbIspE have been hampered by poor solubility of the recombinant enzyme and a failure to obtain crystals (data not shown). To investigate whether the AaIspE structure represents a model system to support inhibitor development we compared the sequences (Fig. 7).

In the above sections we detailed 17 AaIspE residues that interact with CDPME (directly or via water molecules) or that contribute to the placement of functional groups that bind the substrate. Of these, 11 residues are strictly conserved. Five of the remainder are not significant because either main-chain groups interact by hydrogen-bonding interactions (Ala129 → Ser, Lys145 → Arg, Gly172 → Ser), there are solvent bridges involved (Ser97 → Ala, Ser176 → Asn) or in the case of the Ser/Asn change a direct interaction might occur. The final difference is Ser128 → Gly. Ser128 OG interacts with the β-phosphate of CDPME. Truncation of the side chain to glycine might allow a water molecule to compensate for the loss of such an interaction. Similar observations apply when comparing the ATP-binding site. Of the 21 residues discussed above, 10 are strictly conserved and they are mainly those residues that make direct interactions with ATP. Three changes (Ala91 → Gly, Leu93 → Met, Ser169 → Leu) involve residues that interact using main-chain groups, or that use side chains to form the hydrophobic purine binding pocket, e.g. Pro89 → Val. Two alterations are of note. In AaIspE, the side-chain carbonyl groups of Asn60 and Asn99 accept hydrogen bonds from adenine N7 (Fig. 10B). In the sequence alignment shown in Fig. 8, Asn60 and Asn99 correspond to Arg69 (a major alteration) and Asp109 (a conservative change) of MtbIspE, respectively. There may be some difference in MtbIspE such that Asn70 is actually placed to provide the same function as Asn60 of AaIspE.


We purified soluble recombinant AaIspE in high yield, optimized the enzyme assay and kinetically characterized the enzyme, identified conditions that provide a reliable source of well-ordered crystals and determined a series of structures with physiologically relevant ligands. We designed and synthesized a fragment to mimic a component of the substrate and provide a template for inhibitor development. Surprisingly, when soaked into a crystal the ligand adopts a position that overlays where cofactor binds rather than substrate. The collection of structures serves to inform on aspects of specificity and reactivity of IspE. Sequence–structure comparisons indicate that the active site and interactions with ligands are highly conserved and that AaIspE represents a suitable model for orthologues derived from human pathogens including the important M. tuberculosis. We have shown that the crystals are suitable for soaking in small ligands and as such can support a fragment and structure-based approach to underpin drug discovery targeting important human diseases [26,27].

Experimental procedures

Cloning, expression and purification

The gene-encoding sequence of AaIspE was identified in the UniProt Database (entry O67060) and cloned from genomic DNA by PCR using the following primers (NdeI and XhoI restriction sites are underlined): forward: CATATGATAAAGGTTCTATCACCCGCG, reverse: CTCGAGTTAGAGTTCTAGCTCTACAAC. The gene was inserted into the pCR blunt II TOPO vector (Invitrogen, Carlsbad, CA), and then subcloned into the pET15b vector (Novagen, Darmstadt, Germany) which was heat-shock transformed into E. coli BL21 (DE3). Cells were cultured in Luria–Bertani broth containing ampicillin (100 mg·L−1) at 37 °C. Protein production was induced overnight at 30 °C by addition of 1 mm isopropyl-β-d-thiogalactoside. Following centrifugation, cells were resuspended in 50 mm.

Tris/HCl pH 8.5, 250 mm NaCl and 3 mmβ-mercaptoethanol and lysed using a French Press. Cell debris was removed by centrifugation at 40 000 g and the supernatant containing soluble protein was loaded onto a 5 mL Ni2+ HisTrap column (GE Healthcare, Amersham, UK). AaIspE was eluted with a linear imidazole gradient. The His6 tag was removed by digestion with thrombin for 6 h at 4 °C and the sample dialysed against 50 mm Tris/HCl pH 8.5, 50 mm NaCl and 1 mm dithiothreitol. This was then applied to a 5 mL HiTrapQ HP anion-exchange column (GE Healthcare) and AaIspE eluted with a linear NaCl gradient. After dialysis against 10 mm Tris/HCl pH 8.5, 20 mm NaCl and 1 mm dithiothreitol, the protein was concentrated with centrifugal force (VivaSpin20, molecular mass cut-off 10 kDa; Vivascience, Littleton, MA). Concentration was estimated using a theoretical extinction coefficient of 0.898 g·L−1 at 280 nm. The purity of the sample was assessed by SDS/PAGE and MALDI-TOF MS.

To produce the SeMet derivative, the AaIspE/pET15b plasmid was transformed into the E. coli methionine auxotroph B834Met (Stratagene, La Jolla, CA). Cultures were grown in M9 minimal media supplemented with 4 mg·L−1 FeSO4.7H2O and 0.5 g·L−1 each of adenine, guanosine, thymine and uracil. We added 40 mg·L−1 of all amino acids with the exception of methionine, which was replaced by 100 mg·L−1 SeMet (Sigma Aldrich, Poole, UK). Protein production and purification were carried out as described for the native protein. Full incorporation of SeMet was confirmed by MALDI-TOF MS.

Photometric assay for IspE enzyme activity

Assay mixtures contained 100 mm Tris/HCl, pH 8.5, 20 mm KCl, 10 mm MgCl2, 0.45 mm NADH, 2 mm ATP, 4 mm phosphoenolpyruvate, 1 mm CDPME, 8 U pyruvate kinase, 9 U lactate dehydrogenase and 3 μg AaIspE. The assay mixtures were incubated at 37 °C, and the reaction monitored photometrically at 340 nm.

NMR assay for IspE enzyme activity

Assay mixtures contained 100 mm Tris/HCl, pH 8.5, 2 mm MgCl2, 2.5 mm [1,3,4-13C3]CDPME, 8 mm ATP, 23–100 μg AaIspE, 5 mm divalent metal ions and 10% (v/v) D2O in a total volume of 500 μL. The mixtures were incubated at 37 °C for 30–60 min, terminated by the addition of EDTA to a final concentration of 25 mm and analysed by 13C NMR spectroscopy. This assay was used to determine the temperature and metal-ion dependence.

Synthesis of conjugated the fluoro-MEP analogue

All reactions were performed under an inert argon atmosphere. Anhydrous tetrahydrofuran, dichloromethane (DCM) and diethyl ether were obtained through a Pure Solv 400-5MD solvent purification system (Innovative Technology, Inc., Cleveland, OH). All reagents purchased from commercial sources were used without further purification, unless otherwise stated. Solvents were evaporated under reduced pressure at 35 °C using a Büchi Rotavapor. Proton magnetic resonance spectra (1H NMR) were recorded at 400 MHz using Bruker Avance400 or Bruker DPX400 instruments. Chemical shifts, δ are reported in parts per million (p.p.m.), and are referenced to the residual solvent peak. The order of citation in parentheses is (a) number of equivalent nuclei (by integration), (b) multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), (c) coupling constant, with J quoted in Hertz to the nearest 0.5 Hz and (d) assignment. Carbon magnetic resonance spectra (13C NMR) were recorded at 101 MHz using Bruker Avance400 or Bruker DPX400 instruments. Chemical shifts are quoted in p.p.m. and are referenced to the residual solvent peak. The assignment is quoted in parentheses. Fluorine magnetic resonance spectra (19F NMR) were recorded at 376 MHz using a Bruker Avance400 instrument referenced to CFCl3. Phosphorus magnetic resonance spectra (31P NMR) were recorded at 162 MHz using a Bruker Avance400 instrument and are referenced to external phosphoric acid (δ 0.00 p.p.m.). High-resolution mass spectra were recorded on a JEOL JMS-700 spectrometer by electrospray ionization mass spectrometer operating at a resolution of 15 000 full widths at half height.

Infrared spectra were recorded as thin films on NaCl plates using a JASCO FT/IR 4100 instrument. Only significant absorptions (υmax) are reported in wavenumbers (cm−1) with the following abbreviations to describe absorption intensity: w, weak; m, medium; s, strong; and br, broad. Optical rotations, [α]D values were recorded on a Rudolph Research analytical Autopol V automatic polarimeter at 25 °C, with the concentration and solvent reported in brackets. Flash chromatography was carried out using silica gel (Apollo Scientific Gel 60, 40–63 μm) as the stationary phase. TLC was carried out using aluminium sheets pre-coated with silica (Merck Silica Gel 60 F254). Detection was under a UV light source (λmax 254 nm) or through staining with anisaldehyde or potassium permanganate solution, with subsequent heating. RF (retention factor) values are quoted to ± 0.05. The specific details and characterization of compounds are given below and in Ghilagaber et al. [28].

1-[2,4-Bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-3-methyl-butoxymethyl]-4-methoxy-benzene, 3

A −78 °C solution of 2-fluoro-4-(4-methoxy-benzyloxy)-2-methyl-butane-1,3-diol 2 (0.27 g, 1.0 mm) in anhydrous DCM (20 mL) was treated with trimethylsilyl trifluoromethanesulfonate (0.7 mL, 4.0 mm) and 2,6-lutidine (0.5 mL, 4.20 mm). The reaction mixture was stirred for 1.5 h at −78 °C, allowed to warm to room temperature, the aqueous layer was extracted with DCM (3 × 20 mL), the combined organic layers were dried over anhydrous magnesium sulfate and the solvent was removed under reduced pressure. The crude product was purified on a silica gel column using ethyl acetate/petroleum ether (15 : 85) to yield 510 mg 1-[2,4-bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-3-methyl-butoxymethyl]-4-methoxy-benzene 4 (quantitative) as a clear oil.

1H NMR (400 MHz, CDCl3): δ = 7.26 (2H, d, J = 8.6 Hz, ArH), 6.88 (2H, d, J = 8.7 Hz, ArH), 4.43 (2H, s, PhCH2), 4.08 (1H, td, J = 7.6, 2.2 Hz, CH), 3.81 (3H, s, OCH3), 3.70 (1H, d, J = 6.2 Hz, CHAHB), 3.65 (2H, m, CH2), 3.42 (1H, ddd, J = 9.6, 7.1, 2.0 Hz, CHAHB), 1.22 (3H, d, JHF = 22.0 Hz, CFCH3), 0.90 (9H, s, 3 × CH3), 0.88 (9H, s, 3 × CH3), 0.08 (6H, s, 2 × CH3), 0.06 (3H, s, CH3), 0.05 (3H, s, CH3).

13C NMR (100 MHz, CDCl3): δ = 159.2 (ArC), 130.6 (ArC), 129.4 (2 × ArCH), 113.8 (2 × ArCH), 98.3 (d, JCF = 172 Hz, CFCH3), 73.0, 72.8, 72.1, 65.9 (d, JCF = 24.4 Hz), 55.4 (OCH3), 26.0 (6 × CH3), 18.4, 18.1, 17.5 (d, JCF = 22.1 Hz), −4.1 (CH3), −5.1 (CH3), −5.2 (CH3), −5.3 (CH3).

19F NMR (400 MHz, CDCl3): δ = −159.20

RF [diethyl ether/petroleum ether (1 : 1)] 0.51

HRMS (ESI) calcd for C25H47FO4Si2 (M + Na+): 486.2997. Found m/z 509.3300.

[α]D = −5.3 (c 1.15; DCM).

IR: υmax (film) 2857 cm−1 (s, O-CH3) and 1253 cm−1 (s, C-F).

2,4-Bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-3-methyl-butan-1-ol, 4

A solution of 1-[2,4-bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-3-methyl-butoxymethyl]-4-methoxy-benzene 3 (0.14 g, 0.29 mm) in anhydrous DCM (2.5 mL) was cooled to −78 °C. Thiophenol (0.04 mL, 0.36 mm) was added, immediately followed by tin (IV) chloride (0.32 mL, 1.0 m in DCM). The resulting mixture was then stirred for exactly 20 min and the reaction was quenched with saturated sodium hydrogen carbonate (10 mL). The aqueous layer was then extracted with DCM (3 × 20 mL), the combined organic layers were dried over anhydrous magnesium sulfate and the solvent was removed under reduced pressure. The crude residue was purified on a silica gel column using ethyl acetate/petroleum ether (1%) to yield 90 mg 2,4-bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-3-methyl-butan-1-ol 4 (86%) as a clear oil.

1H NMR (400 MHz, CDCl3): δ = 3.96 (1H, m, CH), 3.70 (4H, m, 2 × CH2), 2.06 (1H, td, J = 6.3, 1.7 Hz, OH), 1.28 (3H, d, JHF = 22.4 Hz, CFCH3), 0.91 (9H, s, 3 × CH3), 0.90 (9H, s, 3 × CH3), 0.07 (6H, s, 2 × CH3), 0.11 (3H, s, CH3), 0.12 (3H, s, CH3).

13C NMR (100 MHz, CDCl3): δ = 95.9 (CFCH3,JCF =172 Hz), 74.0 (d, JCF = 26.2 Hz), 65.5 (d, JCF = 27.1 Hz), 63.3 (d, JCF = 5.7 Hz), 26.0 (6 × CH3), 18.5, 18.3, 17.9, −5.3 (CH3), −5.2 (CH3), −4.8 (CH3), −4.4 (CH3).

19F NMR (376 MHz, CDCl3): δ = −157.8

RF [ethyl acetate/petroleum ether (2%)] 0.14

[α]D = −2.6 (c 1.16, CH2Cl2)

IR: υmax (film) 1255 cm−1 (s, C-F)

(E)-[3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-fluoro-4-methyl-pent-1-enyl]-phosphonic acid diethyl ester, 6

Dimethyl sulfoxide (90 μL, 1.30 mm) was added to a −78 °C solution of oxalyl chloride (60 μL, 0.65 mm) in anhydrous DCM (5 mL) and the resulting solution was stirred for 15 min. A solution of 2,4-bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-3-methyl-butan-1-ol 4 (0.12 g, 0.33 mm) in anhydrous DCM (5 mL) was added drop wise and the reaction mixture was stirred for a further 30 min at −78 °C. Triethylamine (0.30 mL, 2.15 mL) was then added and the reaction was allowed to warm to room temperature and left to stir for 1 h. A 2 : 1 solution of diethylether and saturated aqueous sodium hydrogen carbonate (45 mL) was added and the aqueous layer was extracted with diethylether (3 × 20 mL). The combined organic layers were dried over anhydrous magnesium sulfate and the solvent removed under reduced pressure. The crude residue (0.15 g) of 2,4-bis-(tert-butyl-dimethyl-silanyloxy)-3,3-dimethyl-butyraldehyde 5 was used straight away without further purification. 1H NMR (400 MHz, CDCl3): δ = 9.56 (1H, dd, J = 5.1, 1.3 Hz, C(O)H), 4.15 (1H, dd, J = 10.8, 1.3 Hz, CH), 3.82 (1H, t, J =10.0 Hz, CHAHB), 3.49 (1H, dd, J = 13.9, 10.0 Hz, CHAHB), 1.32 (3H, d, J = 22.9 Hz, CFCH3), 0.90 (9H, s, 3 × CH3), 0.87 (9H, s, 3 × CH3), 0.05 (12H, m, 4 × CH3). RF [petroleum ether] 0.26

Tetraethyl methylenediphosphonate (0.16 mL, 0.64 mm) in dry tetrahydrofuran (6 mL) was cooled to −78 °C and stirred for 5 min. nBuLi (0.19 mL, 2.5 m sol. in hexane) was added to the phosphate solution and the mixture stirred for 30 min at −78 °C. A solution of the crude butyraldehyde 5 (0.15 g, 0.41 mm) in anhydrous tetrahydrofuran (7 mL) was added, and the resulting solution was stirred for 1 h at −78 °C and then a further 1.5 h at room temperature. The reaction was quenched with 10% ammonium chloride solution (20 mL) and the aqueous layer extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous magnesium sulfate and the solvent removed under reduced pressure. The product was purified on a silica gel column using ethyl acetate/petroleum ether (2%) to yield 160 mg of the desired [3,5-bis-(tert-butyl-dimethyl-silanyloxy)-4-fluoro-4-methyl-pent-1-enyl]-phosphonic acid diethyl ester 6 (quantitative yield over both steps) as a clear oil.

1H NMR (400 MHz, CDCl3): δ = 6.80 (1H, dddd, J = 17.2, 4.3, 2.0 Hz, JHP = 22.1 Hz, CH), 5.93 (1H, ddd, J = 17.2, 1.5, JHP = 22.1 Hz, CH), 4.54 (1H, m, CH), 4.06 (5H, m, 2 × CH2 and CHAHB), 3.63 (1H, m, CHAHB), 1.28 (6H, t, J = 7.1 Hz, CFCH3), 1.13 (3H, d, JHF = 21.8 Hz, CFCH3), 0.87 (9H, s, 3 × CH3), 0.86 (9H, s, 3 × CH3), 0.05 (3H, s, CH3), 0.03 (3H, s, CH3), 0.02 (3H, s, CH3), −0.01 (3H, s, CH3).

13C NMR (100 MHz, CDCl3): δ = 151.0 (d, JCP = 5 Hz), 119.8 (d, JCP = 186.5 Hz), 97.5 (d, JCF = 176.9 Hz), 72.5 (d, JCF = 21.2 Hz), 72.2 (d, JCF = 21.3 Hz), 65.6, 61.8 (appt. t, JCP = 4.9 Hz), 26.0 (3 × CH3), 25.9 (3 × CH3), 18.4, 18.1, 16.8 (d, JCF = 22.2 Hz), 16.5, 16.4, −4.3 (CH3), −5.1 (CH3), −5.2 (CH3), −5.4 (CH3).

19F NMR (376MHz, CDCl3): δ = −160.35

31P NMR (162MHz, CDCl3): δ = 18.48

RF [ethyl acetate/petroleum ether (3 : 7)] 0.22

HRMS (CI+) calcd for C22H49FO5PSi2 (M + H)+: 499.2840. Found m/z 499.2839.

[α]D = −10.6 (c 1.12, CHCl3).

IR: υmax (film) 1258 cm−1 (s, P=O).

4-Fluoro-3,5-dihydroxy-4-methyl-pent-1-enyl)-phosphonic acid diethyl ester, 7

A solution of [3,5-bis-(tert-butyl-dimethyl-silanyloxy)-4-fluoro-4-methyl-pent-1-enyl]-phosphonic acid diethyl ester 6 (0.44 g, 0.88 mm) in anhydrous DCM (2 mL) was treated with 90% trifluoroacetic acid (4.08 mL, 54.93 mm). The resulting solution was stirred at room temperature for 30 min and the volatile solvents were then removed on a rotary evaporator. The product was purified on a silica gel column using DCM/methanol (9 : 1 v/v) to yield 110 mg of the desired 4-fluoro-3,5-dihydroxy-4-methyl-pent-1-enyl)-phosphonic acid diethyl ester 7 (46%) as a clear oil.

1H NMR (400 MHz, CDCl3): δ = 6.87 (1H, ddm, J = 20.8, 17.2 Hz, CH), 6.14 (1H, ddm, J = 21.0, 17.3 Hz, CH), 4.59 (2H, m, CH2 and 2 × OH), 4.07 (4H, m, 2 × CH2), 3.74 (2H, m, CH2), 1.32 (6H, td, J = 7.0 Hz, JHP = 0.9 Hz, 2 × CH3), 1.17 (3H, d, JHF = 22.2 Hz, CFCH3).

13C NMR (100 MHz, CDCl3): δ = 150.8 (d, JCP = 3.9 Hz) 118.5 (d, JCP = 188 Hz), 97.0 (d, JCF = 173.8 Hz), 71.9 (d, JCF = 71.9 Hz), 71.6 (d, JCF = 71.6 Hz), 66.1 (d, JCF = 23.0 Hz, CH2), 62.4 (appt. t, J = 5.9 Hz, -CH2CH3), 17.1 (d, JCF = 22.4 Hz, -CFCH3), 16.4 (d, JCP=6.4 Hz, 2×−CH2CH3).

31P NMR (162 MHz, CDCl3): δ = 19.2

19F NMR (376 MHz, CDCl3): δ = −160

RF [DCM/MeOH (9 : 1)] 0.37

HRMS (CI+) calcd for C10H21O5FP (M + H)+: 271.1111. Found m/z 271.1107.

[α]D = −40.1 (c 0.94, CHCl3)

IR: υmax (film) 3403 cm−1 (br, O-H)

(4-Fluoro-3,5-dihydroxy-4-methyl-pent-1-enyl)-phosphonic acid, 1

A solution of 4-fluoro-3,5-dihydroxy-4-methyl-pent-1-enyl)-phosphonic acid diethyl ester 7 (0.14 g, 0.52 mm) in anhydrous DCM (2 mL) was treated with TMSBr (0.46 mL, 3.49 mm) and stirred for 20 h at room temperature. The volatile solvents were removed under vacuum and the resultant residue was treated with a 1 : 1 solution of ethanol/water (4 mL) for 30 min and the solvents were once again removed under reduced pressure. This process was repeated three times and the crude residue was purified on a silica gel column using methanol/DCM (1 → 10%) to yield 60 mg of the desired (4-fluoro-3,5-dihydroxy-4-methyl-pent-1-enyl)-phosphonic acid 1 (51%) as a white solid.

1H NMR (400 MHz, MeOD): δ = 6.80 (1H, ddm, J = 20.9, 17.3 Hz, CH), 6.19 (1H, dd, J = 20.4, 17.8 Hz, CH), 4.95 (4H, s, 4×OH), 4.48 (1H, m, CH), 3.71 (2H, m, CH2), 1.22 (3H, d, JHF=22.1, CFCH3).

13C NMR (100 MHz, MeOD): δ = 148.6, 122.1 (d, JCP =185.4 Hz), 99.59 (d, J=174.2 Hz), 72.4 (d, JCF = 72.5 Hz), 72.2 (d, JCF = 72.3 Hz), 66.2 (d, JCF = 22.7 Hz, CH2), 16.9 (d, JCF = 22.8 Hz, CH3).

31P NMR (162 MHz, MeOD): δ = 16.2

19F NMR (376 MHz, MeOD): δ = 164.3

RF [DCM/MeOH (9 : 1)] 0.05

HRMS (FAB+) calcd for C6H13O5FP (M + H)+: 215.0485. Found m/z 215.0488.

[α]D = 21.4° (c 0.46, CH3OH)

IR: υmax (film) 3410cm−1 (br, O–H)


AaIspE was crystallized by vapor diffusion in hanging drops assembled from 2 μL reservoir and 2 μL protein solution at a concentration of 10 mg·mL−1. A reservoir of 0.1 m Mes pH 6.5, 0.20 m NaCl and 1.50 m (NH4)2SO4 was used for the native protein. Crystals of SeMet AaIspE grew with a reservoir of 0.1 m Mes pH 6.5, 0.50 m NaBr and 1.55 m (NH4)2SO4. Triangular prisms (maximum dimension 0.4 mm) grew after a few days at 18 °C. SeMet and native AaIspE (complex I) were co-crystallized with 4 mm AMP-PNP and 4 mm CDP. Crystals were also grown in the presence of 20 mm ADP, 20 mm CDPME2P and 10 mm MgCl2 (complex II). For soaking experiments to obtain complex III, a stabilizing solution of 0.1 m Mes pH 6.5, 0.2 m NaCl and 1.8 m (NH4)2SO4 was used and crystals soaked overnight with compound 1 at a concentration of 25 mm.

Data collection and processing

Following cryo-protection for 30 s (1 : 1 mixture of reservoir with 100% 2-methyl-2,4-pentanediol) the crystals were cooled in a stream of nitrogen gas at −170 °C for data collection. Anomalous dispersion measurements were carried out on SeMet crystals using beam-line ID14-4 at the European Synchrotron Radiation Facility (Grenoble, France). A fluorescence scan around the Se K-edge identified the wavelengths for multiple-wavelength anomalous dispersion data collection. Data were collected at a peak: λ1 = 0.97947 Å, an inflection point: λ2 = 0.97958 Å and a high-energy remote point: λ3 = 0.97625 Å using a Q315 ADSC CCD detector. The SeMet crystals are cubic, in space group P213 with a unit cell edge of 137.8 Å and diffracted to 2.7 Å resolution.

Data were collected on beam-line ID23-1 at the E.S.R.F. on a Q315 ADSC CCD detector or in-house using a Rigaku 007 Micromax rotating-anode generator (Cu Kα,λ = 1.5418 Å) operating at 30 mA and 40 kV, coupled to an R-AXIS IV++ dual image plate system. Data were processed and scaled with mosflm/scala [29,30] or denzo/scalepack [31]. Statistics are shown in Tables 3 and 4.

Structure determination

The program solve [32] identified three of four selenium positions using data to 3.0 Å resolution and gave a figure-of-merit of 0.34 and a Z-score of 13. After density modification with resolve [33], the figure-of-merit increased to 0.72 and a correlation coefficient of 0.38 was obtained. resolve built an initial model of 446 (of 658) residues. The missing residues were included by interpretation of electron density using coot [34]. The model was used to initiate refinement of the ligand complexes using first molrep [35] then refmac [36]. Calculation of Rfree used 5% of the data. Electron density and difference density maps, all σA-weighted [37,38] were inspected and the model improved using coot. A subset of the data (5%) was set aside for calculation of Rfree. Electron and difference density map inspection, model manipulation together with addition of ligands including water molecules was carried out using coot interspersed with TLS (translation, libration, screw analysis) and maximum-likelihood restrained refinement with refmac. Strict non-crystallographic symmetry restraints were applied at first then released towards the end of each refinement. The quality of the model was assessed with procheck [39]. Figures were prepared with chemdraw (Adept Scientific, Letchworth Garden City, UK) pymol ( [40] and aline (C. S. Bond, personal communication).

Quaternary structure

Analytical gel-filtration chromatography used a Superose 10/300 analytical gel-filtration column (GE Healthcare) pre-equilibrated with buffer and calibrated with molecular mass standards, blue dextran (> 2000 kDa), BSA (67 kDa), carbonic anhydrase (29.5 kDa) and cytochrome c (12.5 kDa; GE Healthcare; data not shown). AaIspE eluted at a volume of 94 mL corresponding to an approximate molecular mass of 30.0 kDa. Samples for analytical ultracentrifugation were prepared in the crystallization buffer (see above) at concentrations of 0.25, 0.5 and 1.0 mg·mL−1. Sedimentation velocity experiments were performed using a Beckman Coulter (Fullerton, CA, USA) XL-1 analytical ultracentrifuge (wavelength 280 nm, rotor AN50-TI at 45 000 r.p.m. and 20 °C). Samples were centrifuged simultaneously and A280 measurements taken at 5 min intervals for 16 h. The resultant data were analysed using sedfit and sednterp [41,42]. Analytical ultracentrifugation returned a sedimentation coefficient of 2.61s, which corresponds to a mass of ~ 29.8 kDa (data not shown).


This research was supported by the German Academic Exchange Service (DAAD), the Munich Center for integrated Protein Science, Scottish Enterprise, The Wellcome Trust, the Biotechnology and Biological Science Research Council (Structural Proteomics of Rational Targets) and the European Synchrotron Radiation Facility. We thank R. Huber for a gift of A. aeolicus DNA and I. Hallyburton for technical support.



Aquifex aeolicus IspE
adenosine 5′-(β,γ-imino)triphosphate
4-diphosphocytidyl-2C-methyl-d-erythritol 2-phosphate
Escherichia coli, IspE
GHMP kinase
galacto, homoserine, mevalonate, and phosphomevalonate kinases
4-diphosphocytidyl-2C-methyl-d-erythritol kinase
Mycobacterium tuberculosis IspE
Thermus thermophilus IspE


1. Rohmer M. A mevalonate-independent route to isopentenyl diphosphate. In: Cane DE, editor. Comprehensive Natural Products Chemistry, Vol. 2. Isoprenoids Including Carotenoids and Sterols. Oxford: Pergamon; 1999. pp. 45–67.
2. Edwards PA, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem. 1999;68:157–185. [PubMed]
3. Gershenzon J, Dudareva N. The function of terpene natural products in the natural world. Nat Chem Biol. 2007;3:408–414. [PubMed]
4. Hunter WN. The non-mevalonate pathway of isoprenoid precursor biosynthesis. J Biol Chem. 2007;282:21573–21577. [PubMed]
5. Boucher Y, Doolittle WF. The role of lateral gene transfer in the evolution of isoprenoid biosynthesis pathways. Mol Microbiol. 2000;37:703–716. [PubMed]
6. Kuzuyama T. Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units. Biosci Biotechnol Biochem. 2002;66:1619–1627. [PubMed]
7. Rohdich F, Kis K, Bacher A, Eisenreich W. The non-mevalonate pathway of isoprenoids: genes, enzymes and intermediates. Curr Opin Chem Biol. 2001;5:535–540. [PubMed]
8. Illarionova V, Kaiser J, Ostrozhenkova E, Bacher A, Fischer M, Eisenreich W, Rohdich F. Nonmevalonate terpene biosynthesis enzymes as antiinfective drug targets: substrate synthesis and high-throughput screening methods. J Org Chem. 2006;71:8824–8834. [PubMed]
9. Lüttgen H, Rohdich F, Herz S, Wungsintaweekul J, Hecht S, Schuhr CA, Fellermeier M, Sagner S, Zenk MH, Bacher A, et al. Biosynthesis of terpenoids: YchB protein of Escherichia coli phosphorylates the 2-hydroxy group of 4-diphosphocytidyl-2C-methyl-d-erythritol. Proc Natl Acad Sci USA. 1999;97:1062–1067. [PubMed]
10. Kuzuyama T, Takagi M, Kaneda K, Dairi T, Seto H. Formation of 4-(cytidine 5′-diphospho)-2-C-methyl-d-erythritol from 2-C-methyl-d-erythritol 4-phosphate by 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase, a new enzyme in the nonmevalonate pathway. Tetrahedron Lett. 2000;41:703–706.
11. Bork P, Sander C, Valencia A. Convergent evolution of similar enzymatic function on different protein folds: the hexokinase, ribokinase, and galactokinase families of sugar kinases. Protein Sci. 1993;2:31–40. [PubMed]
12. Cheek S, Zhang H, Grishin NV. Sequence and structure classification of kinases. J Mol Biol. 2002;320:855–881. [PubMed]
13. Miallau L, Alphey MS, Kemp LE, Leonard GA, McSweeney SM, Hecht S, Bacher A, Eisenreich W, Rohdich F, Hunter WN. Biosynthesis of isoprenoids: crystal structure of 4-diphosphocytidyl-2C-methyl-d-erythritol kinase. Proc Natl Acad Sci USA. 2003;100:9173–9178. [PubMed]
14. Wada T, Kuzuyama T, Satoh S, Kuramitsu S, Yokoyama S, Unzai S, Tame JR, Park SY. Crystal structure of 4-(cytidine 5′-diphospho)-2-C-methyl-d-erythritol kinase, an enzyme in the non-mevalonate pathway of isoprenoid synthesis. J Biol Chem. 2003;278:30022–30027. [PubMed]
15. Rohdich F, Wungsintaweekul J, Fellermeier M, Sagner S, Herz S, Kis K, Eisenreich W, Bacher A, Zenk MH. Cytidine 5′-triphosphate-dependent biosynthesis of isoprenoids: YgbP protein of Escherichia coli catalyzes the formation of 4-diphosphocytidyl-2-C-methylerythritol. Proc Natl Acad Sci USA. 1999;96:11758–11763. [PubMed]
16. Bernal C, Mendez E, Terencio J, Boronat A, Imperial S. A spectrophotometric assay for the determination of 4-diphosphocytidyl-2-C-methyl-d-erythritol kinase activity. Anal Biochem. 2005;340:245–251. [PubMed]
17. Rohdich F, Wungsintaweekul J, Luttgen H, Fischer M, Eisenreich W, Schuhr CA, Fellermeier M, Schramek N, Zenk MH, Bacher A. Biosynthesis of terpenoids: 4-diphosphocytidyl-2-C-methyl-d-erythritol kinase from tomato. Proc Natl Acad Sci USA. 2000;97:8251–8256. [PubMed]
18. Zhou T, Daugherty M, Grishin NV, Osterman AL, Zhang H. Structure and mechanism of homoserine kinase: prototype for the GHMP kinase superfamily. Structure. 2000;8:1247–1257. [PubMed]
19. Sgraja T, Smith TK, Hunter WN. Structure, substrate recognition and reactivity of Leishmania major mevalonate kinase. BMC Struct Biol. 2007;7:20. [PMC free article] [PubMed]
20. Holm L, Sander C. Alignment of three-dimensional protein structures: network server for database searching. Methods Enzymol. 1996;266:653–662. [PubMed]
21. Krishna SS, Zhou T, Daugherty M, Osterman AL, Zhang H. Structural basis for the catalysis and substrate specificity of homoserine kinase. Biochemistry. 2001;40:10810–10818. [PubMed]
22. Fu Z, Wang M, Potter D, Miziorko HM, Kim JJ. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. J Biol Chem. 2002;277:18134–18142. [PubMed]
23. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. 2005. WHO Report (
24. Buetow L, Brown AC, Parish T, Hunter WN. The structure of Mycobacteria 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery. BMC Struct Biol. 2007;7:68. [PMC free article] [PubMed]
25. Eoh H, Brown AC, Buetow L, Hunter WN, Parish T, Kaur D, Brennan PJ, Crick DC. Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-d-erythritol synthase: potential for drug development. J Bacteriol. 2007;189:8922–8927. [PMC free article] [PubMed]
26. Hubbard RE, Chen I, Davis B. Informatics and modeling challenges in fragment-based drug discovery. Curr Opin Drug Discov Dev. 2007;10:289–297. [PubMed]
27. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 2007;6:211–219. [PubMed]
28. Ghilagaber S, Hunter WN, Marquez R. Enantioselective synthesis of C3 fluoro-MEP. Org Biomol Chem. 2007;5:97–102. [PubMed]
29. Leslie AGW. The integration of macromolecular diffraction data. Acta Crystallogr D. 2006;62:48–57. [PubMed]
30. Evans P. Scaling and assessment of data quality. Acta Crystallogr D. 2006;62:72–82. [PubMed]
31. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326.
32. Terwilliger TC, Berendzen J. Automated MAD and MIR structure solution. Acta Crystallogr D. 1999;55:849–861. [PMC free article] [PubMed]
33. Terwilliger TC. Maximum-likelihood density modification. Acta Crystallogr D. 2000;56:965–972. [PMC free article] [PubMed]
34. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. 2004;60:2126–2132. [PubMed]
35. Vagin A, Teplyakov A. An approach to multi-copy search in molecular replacement. Acta Crystallogr D. 2000;56:1622–1624. [PubMed]
36. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-liklihood method. Acta Crystallogr D. 1997;53:240–255. [PubMed]
37. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D. 1994;50:760. [PubMed]
38. Read RJ. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr A. 1996;42:140–149.
39. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–291.
40. DeLano WL. The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific; 2002.
41. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J. 2000;78:1606–1619. [PubMed]
42. Lebowitz J, Lewis MS, Schuck P. Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci. 2002;11:2067–2079. [PubMed]
43. Cruickshank DW. Remarks about protein structure precision. Acta Crystallogr D. 1999;55:583–601. [PubMed]

Articles from Wiley-Blackwell Online Open are provided here courtesy of Wiley-Blackwell, John Wiley & Sons